Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.45 -0.7%	$1.31	$0.99 ▼ $5.17	$157.01M	0.42	1.19 million shs	750,839 shs
EPRX Eupraxia Pharmaceuticals	$3.93	$3.58	$2.20 ▼ $4.48	$140.89M	N/A	13,058 shs	7,576 shs
PRAN Alterity Therapeutics	$4.64 +6.7%	$1.41	$1.09 ▼ $2.91	$41.30M	1.05	130,956 shs	14,722 shs
SLN Silence Therapeutics	$5.90 -0.7%	$3.57	$1.97 ▼ $22.47	$176.59M	1.2	301,350 shs	188,892 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+3.55%	+15.87%	+9.77%	-26.63%	+44.55%
EPRX Eupraxia Pharmaceuticals	+1.55%	+3.83%	-0.51%	-1.13%	+41.37%
PRAN Alterity Therapeutics	+1.64%	+8.48%	+25.00%	+12.40%	+123.08%
SLN Silence Therapeutics	+14.45%	+22.73%	+74.71%	+32.00%	-72.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.4546 of 5 stars	3.6	1.0	0.0	0.0	2.6	1.7	1.3
EPRX Eupraxia Pharmaceuticals	2.1646 of 5 stars	3.7	1.0	0.0	0.0	2.5	0.0	0.6
PRAN Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	3.7634 of 5 stars	4.4	4.0	0.0	0.0	3.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$9.71	569.95% Upside
EPRX Eupraxia Pharmaceuticals	3.33	Buy	$10.50	167.18% Upside
PRAN Alterity Therapeutics	0.00	N/A	N/A	N/A
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	473.45% Upside

Current Analyst Ratings Breakdown

Latest PRAN, SLN, EPRX, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00
3/18/2025	ACRS Aclaris Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight
3/7/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$15.00
3/7/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/5/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$49.00 ➝ $45.00
3/4/2025	ACRS Aclaris Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$17.78M	8.83	N/A	N/A	$2.22 per share	0.65
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
PRAN Alterity Therapeutics	$150K	275.31	N/A	N/A	$1.40 per share	3.31
SLN Silence Therapeutics	$27.70M	6.37	N/A	N/A	$0.71 per share	8.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$88.48M	-$1.39	N/A	N/A	N/A	-136.65%	-40.26%	-31.71%	8/6/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$28.22M	-$0.76	N/A	N/A	N/A	N/A	-219.64%	-96.00%	8/6/2025 (Estimated)
PRAN Alterity Therapeutics	-$6.40M	-$0.70	N/A	∞	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	-$53.82M	-$1.50	N/A	N/A	N/A	-342.00%	-62.81%	-33.89%	N/A

Latest PRAN, SLN, EPRX, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A
3/20/2025	Q4 2024	EPRX Eupraxia Pharmaceuticals	-$0.20	-$0.21	-$0.01	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRAN Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	7.03	7.03
EPRX Eupraxia Pharmaceuticals	N/A	4.17	4.17
PRAN Alterity Therapeutics	N/A	4.37	N/A
SLN Silence Therapeutics	N/A	9.31	9.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
EPRX Eupraxia Pharmaceuticals	N/A
PRAN Alterity Therapeutics	3.63%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
EPRX Eupraxia Pharmaceuticals	N/A
PRAN Alterity Therapeutics	38.80%
SLN Silence Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	66.86 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.85 million	N/A	N/A
PRAN Alterity Therapeutics	14	8.90 million	N/A	Not Optionable
SLN Silence Therapeutics	100	29.93 million	N/A	Not Optionable

PRAN, SLN, EPRX, and ACRS Headlines

Recent News About These Companies

Silence Therapeutics plc (NASDAQ:SLN) Shares Bought by Woodline Partners LP

May 27 at 4:38 AM | marketbeat.com

Point72 Asset Management L.P. Has $4.36 Million Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

May 22, 2025 | marketbeat.com

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

May 21, 2025 | zacks.com

Silence Therapeutics plc (NASDAQ:SLN) Receives Average Recommendation of "Moderate Buy" from Analysts

May 15, 2025 | marketbeat.com

Integral Health Asset Management LLC Takes Position in Silence Therapeutics plc (NASDAQ:SLN)

May 14, 2025 | marketbeat.com

What is William Blair's Forecast for SLN FY2027 Earnings?

May 14, 2025 | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Price Target Lowered to $35.00 at Chardan Capital

May 11, 2025 | marketbeat.com

Silence Therapeutics (SLN) Projected to Post Quarterly Earnings on Thursday

May 10, 2025 | marketbeat.com

Silence Therapeutics plc GAAP EPS of -C$0.20

May 8, 2025 | seekingalpha.com

Cantor Fitzgerald L. P. Buys 205,534 Shares of Silence Therapeutics plc (NASDAQ:SLN)

May 7, 2025 | marketbeat.com

Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | finanznachrichten.de

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | businesswire.com

Silence Therapeutics plc (NASDAQ:SLN) Stock Holdings Increased by Nantahala Capital Management LLC

April 30, 2025 | marketbeat.com

Boothbay Fund Management LLC Has $2.42 Million Position in Silence Therapeutics plc (NASDAQ:SLN)

April 30, 2025 | marketbeat.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

March 4, 2025 | zacks.com

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

March 1, 2025 | uk.finance.yahoo.com

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

February 28, 2025 | seekingalpha.com

Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner

February 28, 2025 | biospace.com

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

February 27, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAN, SLN, EPRX, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.45 -0.01 (-0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$1.46 +0.01 (+0.69%)

As of 07:19 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$3.93 0.00 (0.00%)

Closing price 03:59 PM Eastern

Extended Trading

$3.89 -0.04 (-1.02%)

As of 05:26 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Alterity Therapeutics NASDAQ:PRAN

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Silence Therapeutics NASDAQ:SLN

$5.90 -0.04 (-0.67%)

Closing price 04:00 PM Eastern

Extended Trading

$5.81 -0.09 (-1.53%)

As of 06:51 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time